Latest Regulatory Milestones News

Page 17 of 84
Cleo Diagnostics reported a 53% drop in revenues and a slight increase in net loss to $1.98 million for H1 2025, while progressing its pivotal FDA clinical trial for an ovarian cancer blood test with strong regulatory and commercial milestones.
Ada Torres
Ada Torres
25 Feb 2026
Immuron Limited reported a narrower half-year loss alongside record sales growth and FDA approval for its IMM-529 drug candidate, signalling promising clinical and commercial momentum.
Ada Torres
Ada Torres
25 Feb 2026
Optiscan Imaging reports a sharp 43% drop in revenue and a 43% rise in losses for H1 FY26, driven by restricted research funding in key markets. The company bolsters its balance sheet with a $17.75 million capital raise to advance clinical studies and regulatory approvals.
Ada Torres
Ada Torres
25 Feb 2026
Epiminder Limited has reported a $21.7 million loss for the half-year ending December 2025, alongside a successful $125 million IPO that fuels its commercialisation of the FDA-approved Minder epilepsy monitoring device.
Ada Torres
Ada Torres
25 Feb 2026
Imricor Medical Systems saw a sharp 69.5% decline in revenue for 2025, driven by clinical trial impacts, yet narrowed its net loss to $25.3 million as it secured FDA clearance for key products post-year-end.
Ada Torres
Ada Torres
25 Feb 2026
Prescient Therapeutics reported a 62.8% increase in half-year losses to nearly $4 million, driven by intensified clinical development of its PTX-100 cancer therapy. The company bolstered its balance sheet with a $9.85 million capital raise while securing key regulatory milestones in Europe and the US.
Ada Torres
Ada Torres
24 Feb 2026
Singular Health Group reported a 55% rise in net loss to $2.97 million for H1 FY2026, driven by share-based payments and strategic hires, while making significant progress in US commercial deployments and securing FDA clearance for its cloud-based 3D medical imaging platform.
Ada Torres
Ada Torres
24 Feb 2026
PYC Therapeutics reported a narrowed half-year loss of $22.8 million while progressing four RNA drug candidates through clinical stages. The company announced a major $653 million capital raising to extend its cash runway to 2030 and support ongoing development.
Ada Torres
Ada Torres
23 Feb 2026
Norfolk Metals has confirmed the US$250,000 option payment for the Carmen Copper Project in Chile and completed the environmental impact report, setting the stage for further exploration and eventual ownership consolidation.
Maxwell Dee
Maxwell Dee
23 Feb 2026
Critical Resources Limited has identified three priority targets at its Lammerlaw Gold Project in New Zealand, validating the area’s gold potential ahead of permit approval and outlining a cost-effective exploration strategy.
Maxwell Dee
Maxwell Dee
23 Feb 2026
Paladin Energy has achieved a significant regulatory milestone with formal environmental approval for its Patterson Lake South uranium project in Saskatchewan, Canada, paving the way for construction licensing.
Maxwell Dee
Maxwell Dee
20 Feb 2026
PolyNovo Limited reported a robust 25.2% increase in half-year revenue to A$75 million, driven by strong U.S. sales and product growth, despite a near break-even net profit impacted by a manufacturing slowdown and a fire at its R&D lab.
Ada Torres
Ada Torres
20 Feb 2026